Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195373 | 1.00 | CCR2 (1.00) | CCR2RAB9AALDH1A1KDM4ENPC1 | |
| SCHEMBL12292044 | 0.99 | CCR2 (0.97) | CCR2RAB9AALDH1A1KDM4ENPC1 | |
| SCHEMBL3802103 | 0.96 | CCR2 (0.92) | CCR2RAB9AALDH1A1KDM4E | |
| SCHEMBL12292042 | 0.96 | CCR2 (0.92) | CCR2RAB9AALDH1A1KDM4E | |
| SCHEMBL12292046 | 0.90 | CCR2 (0.81) | CCR2ALDH1A1 | |
| SCHEMBL13483782 | 0.87 | CCR2 (0.77) | CCR2RAB9AALDH1A1KDM4E | |
| SCHEMBL12799207 | 0.87 | CCR2 (0.77) | CCR2RAB9AALDH1A1KDM4E | |
| SCHEMBL13013126 | 0.86 | CCR2 (0.75) | CCR2RAB9AKDM4E | |
| SCHEMBL12849249 | 0.86 | CCR2 (0.75) | CCR2RAB9AALDH1A1KDM4ENPC1 | |
| SCHEMBL3259739 | 0.82 | CCR2 (0.69) | CCR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | disclosed |
| EP-1781299-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7662967-B2 | Anti-inflammatory compounds and compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | CAMBRIDGE ENTERPRISE LIMITED THE OLD SCHOOLS (GB) | 2009-02-05 | — | — | US | disclosed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194541-A1 | Anti-Inflammatory Agents | TNF, IL1RN, FPR1 | CCR2 96/4885RAB9A 2491/4885ALDH1A1 2239/4885 |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | TNF, NFKBIA, TPMT | CCR2 207/4885RAB9A 3490/4885ALDH1A1 856/4885 |
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885RAB9A 2291/4885ALDH1A1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.